{"id":"https://openalex.org/W4380079400","doi":"https://doi.org/10.1002/hon.3164_324","title":"Five\u2010year subgroup analysis of tafasitamab + lenalidomide from the Phase II L\u2010MIND study in patients with relapsed or refractory diffuse large B\u2010cell lymphoma","display_name":"Five\u2010year subgroup analysis of tafasitamab + lenalidomide from the Phase II L\u2010MIND study in patients with relapsed or refractory diffuse large B\u2010cell lymphoma","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4380079400","doi":"https://doi.org/10.1002/hon.3164_324","pmid":"https://pubmed.ncbi.nlm.nih.gov/39112163"},"language":"en","primary_location":{"id":"doi:10.1002/hon.3164_324","doi":"https://doi.org/10.1002/hon.3164_324","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3164_324","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_324","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_324","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061317839","display_name":"Johannes Duell","orcid":"https://orcid.org/0000-0001-6935-7997","observed_orcids":["https://orcid.org/0000-0001-6935-7997"]},"institutions":[{"id":"https://openalex.org/I4210126310","display_name":"Universit\u00e4tsklinikum W\u00fcrzburg","ror":"https://ror.org/03pvr2g57","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210126310"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"J. Duell","raw_affiliation_strings":["Medizinische Klinik und Poliklinik II Universit\u00e4tsklinik W\u00fcrzburg  W\u00fcrzburg Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medizinische Klinik und Poliklinik II Universit\u00e4tsklinik W\u00fcrzburg  W\u00fcrzburg Germany","institution_ids":["https://openalex.org/I4210126310"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007117385","display_name":"Pau Abrisqueta","orcid":"https://orcid.org/0000-0001-9625-7422","observed_orcids":["https://orcid.org/0000-0001-9625-7422","https://orcid.org/0000-0003-3028-7500"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"P. Abrisqueta","raw_affiliation_strings":["Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046049357","display_name":"Martin H. Dreyling","orcid":"https://orcid.org/0000-0002-0358-5249","observed_orcids":["https://orcid.org/0000-0002-0358-5249"]},"institutions":[{"id":"https://openalex.org/I8204097","display_name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","ror":"https://ror.org/05591te55","country_code":"DE","type":"education","lineage":["https://openalex.org/I8204097"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"M. Dreyling","raw_affiliation_strings":["Ludwig-Maximilians-University Hospital, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ludwig-Maximilians-University Hospital, Munich, Germany","institution_ids":["https://openalex.org/I8204097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041745367","display_name":"Gianluca Ga\u00efdano","orcid":"https://orcid.org/0000-0002-4681-0151","observed_orcids":["https://orcid.org/0000-0002-4681-0151"]},"institutions":[{"id":"https://openalex.org/I123338534","display_name":"Universit\u00e0 degli Studi del Piemonte Orientale \u201cAmedeo Avogadro\u201d","ror":"https://ror.org/04387x656","country_code":"IT","type":"education","lineage":["https://openalex.org/I123338534"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"G. Gaidano","raw_affiliation_strings":["Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy","institution_ids":["https://openalex.org/I123338534"]}]},{"author_position":"middle","author":{"id":null,"display_name":"E. G. Barca","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087039","display_name":"Institut d'Investigaci\u00f3 Biom\u00e9dica de Bellvitge","ror":"https://ror.org/0008xqs48","country_code":"ES","type":"facility","lineage":["https://openalex.org/I157913058","https://openalex.org/I2802050225","https://openalex.org/I4210087039","https://openalex.org/I4210096656","https://openalex.org/I4210106543","https://openalex.org/I4210107147","https://openalex.org/I4210153292","https://openalex.org/I4387153040","https://openalex.org/I71999127"]},{"id":"https://openalex.org/I4210107147","display_name":"Institut Catal\u00e0 d'Oncologia","ror":"https://ror.org/01j1eb875","country_code":"ES","type":"government","lineage":["https://openalex.org/I4210107147"]},{"id":"https://openalex.org/I4210143012","display_name":"Duran i Reynals Hospital","ror":"https://ror.org/03qwghy04","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210143012"]},{"id":"https://openalex.org/I71999127","display_name":"Universitat de Barcelona","ror":"https://ror.org/021018s57","country_code":"ES","type":"education","lineage":["https://openalex.org/I71999127"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"E. G. Barca","raw_affiliation_strings":["Institut Catal\u00e0 d'Oncologia Hospital Duran i Reynals IDIBELL Universitat de Barcelona  Barcelona Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Catal\u00e0 d'Oncologia Hospital Duran i Reynals IDIBELL Universitat de Barcelona  Barcelona Spain","institution_ids":["https://openalex.org/I4210087039","https://openalex.org/I4210107147","https://openalex.org/I4210143012","https://openalex.org/I71999127"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102788725","display_name":"Wojciech J. Jurczak","orcid":"https://orcid.org/0000-0003-1879-8084","observed_orcids":["https://orcid.org/0000-0003-1879-8084"]},"institutions":[{"id":"https://openalex.org/I4210150880","display_name":"The Maria Sklodowska-Curie National Research Institute of Oncology","ror":"https://ror.org/04qcjsm24","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210150880"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"W. Jurczak","raw_affiliation_strings":["Department of Clinical Oncology Maria Sklodowska\u2010Curie National Research Institute of Oncology  Krak\u00f3w Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Oncology Maria Sklodowska\u2010Curie National Research Institute of Oncology  Krak\u00f3w Poland","institution_ids":["https://openalex.org/I4210150880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024389256","display_name":"Kami J. Maddocks","orcid":"https://orcid.org/0000-0001-8519-8404","observed_orcids":["https://orcid.org/0000-0001-8519-8404"]},"institutions":[{"id":"https://openalex.org/I2802841970","display_name":"The Ohio State University Wexner Medical Center","ror":"https://ror.org/00c01js51","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802841970"]},{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. J. Maddocks","raw_affiliation_strings":["Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA","institution_ids":["https://openalex.org/I2802841970","https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074570151","display_name":"Tobias Menne","orcid":"https://orcid.org/0000-0002-3289-2344","observed_orcids":["https://orcid.org/0000-0002-3289-2344"]},"institutions":[{"id":"https://openalex.org/I2801924861","display_name":"Freeman Hospital","ror":"https://ror.org/00cdwy346","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801663869","https://openalex.org/I2801924861"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"T. Menne","raw_affiliation_strings":["Freeman Hospital, The Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Freeman Hospital, The Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK","institution_ids":["https://openalex.org/I2801924861"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101865823","display_name":"Zsolt Nagy","orcid":"https://orcid.org/0000-0001-9756-5427","observed_orcids":["https://orcid.org/0000-0001-9756-5427"]},"institutions":[{"id":"https://openalex.org/I101202996","display_name":"Semmelweis University","ror":"https://ror.org/01g9ty582","country_code":"HU","type":"education","lineage":["https://openalex.org/I101202996"]}],"countries":["HU"],"is_corresponding":false,"raw_author_name":"Z. Nagy","raw_affiliation_strings":["Semmelweis University, Budapest, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Semmelweis University, Budapest, Hungary","institution_ids":["https://openalex.org/I101202996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052071966","display_name":"Olivier Tournilhac","orcid":"https://orcid.org/0000-0002-9438-621X","observed_orcids":["https://orcid.org/0000-0002-9438-621X"]},"institutions":[{"id":"https://openalex.org/I4210128870","display_name":"Centre Hospitalier Universitaire de Clermont-Ferrand","ror":"https://ror.org/02tcf7a68","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128870"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"O. Tournilhac","raw_affiliation_strings":["CHU de Clermont-Ferrand, Clermont Ferrand, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHU de Clermont-Ferrand, Clermont Ferrand, France","institution_ids":["https://openalex.org/I4210128870"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036001420","display_name":"Abhishek Bakuli","orcid":"https://orcid.org/0000-0001-5123-1974","observed_orcids":["https://orcid.org/0000-0001-5123-1974"]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"A. Bakuli","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011014349","display_name":"Aasim Amin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"A. Amin","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029890875","display_name":"Konstantin Gurbanov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"K. Gurbanov","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086354986","display_name":"Gilles A. Salles","orcid":"https://orcid.org/0000-0002-9541-8666","observed_orcids":["https://orcid.org/0000-0002-9541-8666"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Salles","raw_affiliation_strings":["Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":17,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4220,"currency":"USD","value_usd":4220},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.12159017,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"S2","first_page":"439","last_page":"441"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tafasitamab","display_name":"tafasitamab","score":0.972000002861023},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":1.0},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9300000071525574},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9909999966621399},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.6359999775886536},{"id":"https://openalex.org/keywords/international-prognostic-index","display_name":"International Prognostic Index","score":0.8790000081062317},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6990000009536743},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.996999979019165},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.781000018119812},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.6100000143051147},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.5230000019073486}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.8273003101348877},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7960219383239746},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7049397230148315},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5507538914680481},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5494446754455566},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.49595460295677185},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.49428796768188477},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4729052782058716},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.46301576495170593},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4510877728462219},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.4216488003730774},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.418748676776886},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3631599545478821},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3527352809906006},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.32668477296829224},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.3188610076904297},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.2504468560218811},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.20193231105804443},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.19284451007843018},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D003226","descriptor_name":"Congresses as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008223","descriptor_name":"Lymphoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D013557","descriptor_name":"Switzerland","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/hon.3164_324","doi":"https://doi.org/10.1002/hon.3164_324","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3164_324","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_324","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},{"id":"pmid:39112163","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39112163","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological oncology","raw_type":"Congress"}],"best_oa_location":{"id":"doi:10.1002/hon.3164_324","doi":"https://doi.org/10.1002/hon.3164_324","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3164_324","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_324","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":false},"content_urls":{"pdf":"https://content.openalex.org/works/W4380079400.pdf"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4386102498","https://openalex.org/W4386281972","https://openalex.org/W4386271179","https://openalex.org/W3172444569","https://openalex.org/W3112732938","https://openalex.org/W4365514092","https://openalex.org/W4246296409","https://openalex.org/W3176363517","https://openalex.org/W4310127427","https://openalex.org/W2988395771"],"abstract_inverted_index":{"Background:":[0],"The":[1,288],"Phase":[2],"II":[3],"L-MIND":[4,41],"study":[5,205],"led":[6],"to":[7,126,285,304],"accelerated":[8],"US":[9],"approval":[10],"and":[11,77,111,124,172,214,220],"EU":[12],"conditional":[13],"authorization":[14],"of":[15,52,59,105,140,145,204,254,301],"the":[16,45,150,305],"CD19-targeted":[17],"immunotherapy,":[18],"tafasitamab,":[19],"+":[20,243],"lenalidomide":[21],"(LEN)":[22],"followed":[23,245],"by":[24,119,246],"tafasitamab":[25,82,201,242,247],"monotherapy":[26,248],"for":[27,34,83,176,196,217,520],"patients":[28,193],"(pts)":[29],"with":[30,65,132,241,259],"R/R":[31,67],"DLBCL":[32],"ineligible":[33],"autologous":[35],"stem":[36],"cell":[37],"transplant":[38],"(ASCT).":[39],"Long-term":[40],"data":[42,265],"further":[43,278],"support":[44],"regimen.":[46],"Here":[47],"we":[48],"present":[49],"exploratory":[50],"analyses":[51,117],"final":[53],"5-year":[54],"(yr)":[55],"efficacy":[56],"in":[57,149,194,211,226,251,277],"subgroups":[58,229,253],"interest.":[60],"Methods:":[61],"Pts":[62],"(\u226518":[63],"years)":[64],"ASCT-ineligible":[66],"DLBCL,":[68],"1\u20133":[69],"prior":[70,135],"systemic":[71],"therapies":[72],"(incl.":[73],"\u22651":[74],"targeting":[75],"CD20)":[76],"ECOG":[78],"PS":[79],"0\u20132":[80],"received":[81,200],"\u226412":[84],"28-day":[85],"cycles":[86],"(+":[87],"LEN),":[88],"then":[89],"alone":[90],"until":[91,202],"disease":[92],"progression.":[93],"Primary":[94],"endpoint":[95],"was":[96,159,167,178,184,249,290],"objective":[97],"response":[98,106],"rate":[99],"(ORR).":[100],"Secondary":[101],"endpoints":[102],"included":[103],"duration":[104,166],"(DoR),":[107],"progression-free":[108],"survival":[109,113],"(PFS)":[110],"overall":[112],"(OS).":[114],"Exploratory":[115],"subgroup":[116,235],"including":[118,257],"International":[120],"Prognostic":[121],"Index":[122],"(IPI)":[123],"time":[125],"progression":[127],"after":[128],"1L":[129],"(in":[130],"pts":[131,258],"only":[133],"1":[134],"line)":[136],"used":[137],"Kaplan-Meier":[138],"estimates":[139],"5-yr":[141,215,234],"endpoints.":[142],"Results:":[143],"As":[144],"14":[146],"November":[147],"2022":[148],"full":[151],"analysis":[152],"set":[153],"(FAS;":[154],"n":[155],"=":[156],"80),":[157],"ORR":[158],"57.5%":[160],"[95%":[161],"CI:":[162],"45.9\u201368.5].":[163],"Median":[164,182],"treatment":[165],"9.0":[168],"months":[169],"(mo)":[170],"[0.5\u201373.6]":[171],"median":[173],"follow-up":[174,195],"(mFU)":[175],"OS":[177,221],"65.6":[179],"mo":[180,189],"[59.9\u201370.3]).":[181],"DoR":[183],"not":[185],"reached":[186],"(mFU:":[187],"44.0.":[188],"[29.9\u201357.0]).":[190],"Of":[191],"18":[192],"\u22655":[197],"years,":[198],"9":[199,208],"end":[203],"per":[206],"protocol,":[207],"discontinued":[209],"while":[210],"remission.":[212],"RR":[213],"rates":[216],"DoR,":[218],"PFS":[219],"showed":[222],"long-term":[223,238],"clinical":[224,239,255],"activity":[225],"all":[227,252],"pt":[228],"(Table).":[230],"Conclusion:":[231],"In":[232],"this":[233,267],"analysis,":[236],"a":[237],"benefit":[240],"LEN":[244],"observed":[250],"interest,":[256],"poor":[260],"prognosis":[261],"risk":[262],"factors.":[263],"These":[264],"suggest":[266],"immunotherapy":[268],"may":[269],"have":[270],"curative":[271],"potential,":[272],"which":[273],"is":[274],"being":[275],"explored":[276],"studies.":[279],"Encore":[280],"Abstract":[281],"-":[282],"previously":[283],"submitted":[284],"ASCO":[286],"2023":[287],"research":[289],"funded":[291],"by:":[292],"MorphoSys":[293,311,449,459,565,581,593,607,631],"AG":[294,566,582,586,594,632],"Keyword:":[295],"Aggressive":[296],"B-cell":[297],"non-Hodgkin":[298],"lymphoma":[299],"Conflicts":[300],"interests":[302],"pertinent":[303],"abstract.":[306],"J.":[307,455],"Duell":[308],"Research":[309,353,435,478,500],"funding:":[310,354,436,479,501],"AG,":[312,450,460,608],"Regeneron":[313],"P.":[314],"Abrisqueta":[315],"Consultant":[316,341,374,393,424,486,532,545,597],"or":[317,342,375,394,425,487,533,546,562,578,590,598],"advisory":[318,343,376,395,426,488,534,547,599],"role:":[319,344,377,396,427,489,535,548,600],"Janssen,":[320,325,334,349,359,368,382,397,407,414,445,475,502,515,524,537,553,604,625],"Celgene,":[321,326,335,357,605,626],"AbbVie,":[322,327,336,355,378,388,398,408,415,470,538,555,630],"AstraZeneca":[323],"Honoraria:":[324,457,623],"AstraZeneca,":[328,337,345,365,379,433,471,503,550],"Gilead":[329,338,602,627],"Other":[330,361,384,410,517,567],"remuneration:":[331,362,385,411,518,568],"Speakers\u2019":[332],"bureau:":[333,413],"M.":[339],"Dreyling":[340],"BeiGene,":[346,366,380,439,472,551,618],"BMS/Celgene,":[347],"Gilead/Kite,":[348,358,367],"Lilly/Loxo,":[350],"Novartis,":[351,370,492,527,606,629],"Roche":[352,360,371,383],"Bayer,":[356,510],"Speakers'":[363,412],"honoraria:":[364],"Lilly,":[369,403,476],"G.":[372,391,595],"Gaidano":[373],"Incyte,":[381,402,420,443,552,619],"Speaker\u2019s":[386],"Bureau:":[387],"Janssen":[389,499],"E.":[390],"Barca":[392],"Gilead,":[399,554],"Kiowa,":[400,417],"EUSAPharma,":[401,419],"BeiGene":[404,421,434],"Educational":[405,505],"grants:":[406,506],"EUSAPharma":[409],"Takeda,":[416,432,451,523,536,549],"Roche,":[418,498,525,539,556],"W.":[422],"Jurczak":[423],"MEI":[428,447],"Pharma,":[429,448],"Debiopharm,":[430,442],"Loxo,":[431,446],"GSK,":[437],"Acerta,":[438],"Nordic":[440],"Nanovector,":[441],"Genentech,":[444,474],"TG":[452],"Therapeutics":[453],"K.":[454,587],"Maddocks":[456],"Pharmacyclics,":[458,480],"Bristol-Myers":[461,482,616],"Squibb,":[462,617],"Karyopharm":[463],"Therapeutics,":[464,469],"Kite":[465],"Pharma/Gilead":[466],"Company,":[467],"ADC":[468],"Genmab,":[473,612],"Incyte":[477],"Merck,":[481],"Squibb":[483],"T.":[484],"Menne":[485],"Kite/Gilead,":[490,514,522],"Amgen,":[491,507,540],"Pfizer,":[493,509],"Celgene/BMS,":[494,513,528],"Daiichi":[495],"Sankyo,":[496],"Atara,":[497],"Novartis":[504],"Jazz,":[508],"Kyowa":[511],"Kirin,":[512],"Takeda":[516],"Honoraria":[519],"lectures:":[521],"Servier,":[526,541],"Pfizer":[529],"Z.":[530],"Nagy":[531],"Astellas":[542],"O.":[543],"Tournilhac":[544],"Sandoz,":[557],"Blueprint":[558],"A.":[559,575],"Bakuli":[560],"Employment":[561,577,589],"leadership":[563,579,591],"position:":[564,580,592],"statistical":[569],"consultancy:":[570],"Ludwig-Maximilians-University":[571],"Hospital,":[572],"Munich,":[573],"Germany":[574],"Amin":[576],"Stock":[583],"ownership:":[584],"Paion":[585],"Gurbanov":[588],"Salles":[596],"Roche/Genentech,":[601,624],"Sciences,":[603,611,628],"Epizyme,":[609],"Alimera":[610],"Debiopharm":[613],"Group,":[614],"VelosBio,":[615],"Miltenyi":[620],"Biotec,":[621],"Ipsen":[622]},"counts_by_year":[],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2023-06-10T00:00:00"}